Join our daily newsletter At The Bell to receive exclusive market insights
- Emyria (EMD) receives positive results from the first batch of MDMA analogues screened for neuroreceptor activity from pharmaceutical development company, Eurofin
- Results highlighted novel compounds with greater potency compared with MDMA for certain neuroreceptors at the test concentrations
- The company says the early results are promising, with very few compounds excluded due to possible off-target concerns at the test concentrations
- A second batch of compounds from the original analogue library is now being prepared for initial screening
- Emyria is up 6.67 per cent, trading at 40 cents at 1:40 pm AEDT
Emyria (EMD) has received ‘positive’ results from the first MDMA analogues screened for neuroreceptor activity.
In-vitro receptor screening results from the first batch of MDMA analogues were received from the pharmaceutical development company, Eurofin.
Results highlighted novel compounds with greater potency compared with MDMA for certain neuroreceptors at the test concentrations.
Sixty-six of 68 compounds from the initial batch successfully passed screening, showing no evidence of interactions with one or more of the “anti-targets,” or enzyme or cell receptor interactions associated with unwanted side effects, at the test concentrations.
Emyria’s Managing Director, Michael Winlo said the early results are promising, with very few compounds excluded due to possible off-target concerns at the test concentrations.
“These results mean we have multiple compounds with therapeutic potential suitable for further screening and development,” Dr Winlo said.
The second batch of compounds from the original analogue library is now being prepared for initial screening.
Meanwhile, Emyria’s first patent has been filed and further IP filing is in progress.
Emyria was up 6.67 per cent, trading at 40 cents at 1:40 pm AEDT.
